Medicine information · Oncology · Prescription-only

Daraxonrasib: Uses, Brands, Safety and Availability

Daraxonrasib is a once-daily oral RAS inhibitor. In the United States it is approved as RASONQUE for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent chemotherapy.[1][2]

Daraxonrasib, also known as RMC-6236, is a prescription RAS inhibitor. In the US, RASONQUE is approved for adults with metastatic pancreatic adenocarcinoma after prior systemic therapy or when multiagent systemic therapy is unsuitable. Local approval and product eligibility require separate checks.

Prescription, product documents and destination rules are assessed before supply. An enquiry does not guarantee stock, import permission or delivery. Ownership and commercial disclosure

LuciDarax (100–150 mg) pack, manufacturer as listed: Lucius Pharma
LuciDarax · RASONQUE — Product photos as listed[5]
  • 2 brands includedOriginator plus 1 listed product
  • Originator: RASONQUERevolution Medicines · US approval 26 August 2026
  • Regulatory status variesConfirm with your national authority
  • Prescription-only medicineThe dose is decided by the treating oncologist
Quick facts

Daraxonrasib at a glance

Generic name (INN)
Daraxonrasib[1]
Medicine class
RAS inhibitor, taken by mouth[2]
Mechanism
Binds cyclophilin A and forms a complex with active, GTP-bound RAS, blocking signalling downstream of RAS[2]
Dosage form and strengths (US label)
Film-coated tablets, 100 mg and 150 mg (30 per bottle)[2]
Recommended dose (US label)
300 mg once daily until disease progression or unacceptable toxicity[2]
Originator
RASONQUE · Revolution Medicines, Inc.[1][3]
First approval
United States: 26 August 2026[1][3]
Products in this directory
2 brands total · LuciDarax plus the originator RASONQUE[5]
Supply status
Prescription-only medicine[2]

What is daraxonrasib?

Daraxonrasib is the international non-proprietary name of an oral RAS inhibitor. According to the US prescribing information, it binds the protein cyclophilin A and forms a complex with RAS in its active, GTP-bound state, which blocks signalling downstream of RAS.[2]

The US FDA approved it as RASONQUE on 26 August 2026 for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent chemotherapy. The approval was based on the RASolute 302 trial.[1][3]

According to the company, the European Medicines Agency's CHMP has started a phased review, and an orphan medicinal product designation is reported for daraxonrasib. Approved uses and availability differ between countries.[3]

Whether daraxonrasib is suitable, and at which dose, is decided by the treating oncologist. Full warnings are in the official product information:

Directory

1 other product currently included in this directory

The products below are included for identification and availability-enquiry purposes. Inclusion does not mean that a product is authorised, approved, therapeutically equivalent or available in every country. Confirm regulatory status with the relevant national medicines authority.

Products are listed in alphabetical order. The list is not a ranking and makes no claim that one product is better than another.[5]

1 of 1 products

  • LuciDarax (100–150 mg) pack, manufacturer as listed: Lucius Pharma

    LuciDarax

    Product information listed
    Active ingredient as listed
    Daraxonrasib
    Manufacturer as listed
    Lucius Pharma (manufacturing country listed: Laos)
    Product strength (not a dose recommendation)
    100 / 150 mg
    Dosage form
    Tablet
    Pack information
    30 tablets, pot (container)
    Information source
    Product listing dataset[5]
    Information last checked
    October 7, 2026
    Regulatory status
    Not independently verified for this page

Product listing data last checked October 7, 2026.

Originator

Originator medicine: RASONQUE (Revolution Medicines, Inc.)

RASONQUE is the originator daraxonrasib medicine. It was developed by Revolution Medicines, Inc. and approved by the US Food and Drug Administration on 26 August 2026 for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or when multiagent chemotherapy is not suitable.[1][3]

The originator is shown here separately from the other listed products.

Brand name
RASONQUE[1]
Active substance
Daraxonrasib[2]
Company
Revolution Medicines, Inc.[1][3]
Strengths in the US label
Film-coated tablets: 100 mg and 150 mg[2]
Pack in the US label
30 tablets per bottle; store at 20–25 °C[2]
First approval
United States 26 August 2026[1][3]
Comparison

Daraxonrasib generic vs originator medicine

This comparison covers identity and listing information only. It does not establish regulatory approval, pharmaceutical equivalence, bioequivalence, quality, safety or clinical effectiveness.

AttributeOther listed daraxonrasib productOriginator (RASONQUE)
Active substanceDaraxonrasib, as listed. Salt form and formulation are not stated in the product listing.[5]Daraxonrasib[2]
Brand nameLuciDarax, the manufacturer's own brand name[5]RASONQUE[1]
CompanyLucius Pharma (manufacturing country listed: Laos)[5]Revolution Medicines, Inc.[1]
Dosage formTablet, as listed[5]Film-coated tablet[2]
Strengths100 mg and 150 mg, as listed[5]100 mg and 150 mg[2]
Regulatory approvalVaries by country. Not independently verified for this page; check with your national medicines authority.US FDA 26 August 2026[1][3]
ClassificationProduct represented by its manufacturer or supplier as containing daraxonrasib. Regulatory classification must be confirmed in the relevant jurisdiction.[5]Originator product[1]
Safety

Side effects and important warnings

The information below summarises the US prescribing information. It is not complete; read the full label and talk to your oncologist.[2]

No boxed warning, but several important warnings apply. The US label carries no boxed warning. Warnings and precautions include dermatologic and soft-tissue toxicity, stomatitis and other oral disorders, diarrhoea, gastrointestinal perforation, interstitial lung disease/pneumonitis and embryo-fetal toxicity.[2]

Most common side effects (all grades; grade 3–4 in brackets)

Side effectReported as listed in the label
Rash87% (13%)
Diarrhoea67% (7%)
Stomatitis (mouth sores)56% (12%)
Nausea52% (3%)
Fatigue47% (5%)
Vomiting42% (1%)
Abdominal pain27% (2%)
Oedema (swelling)25% (0.8%)
Decreased appetite24% (2%)
Haemorrhage (bleeding)22% (3%)

Warnings and precautions in the label

  • Dermatologic and soft-tissue toxicity
  • Stomatitis and other oral disorders
  • Diarrhoea
  • Gastrointestinal perforation
  • Interstitial lung disease / pneumonitis
  • Embryo-fetal toxicity

Interactions and pregnancy

  • Avoid strong CYP3A inhibitors that also inhibit P-gp. For other CYP3A or P-gp inhibitors the label gives adjusted doses (100 mg, 150 mg or 200 mg depending on the inhibitor).
  • CYP3A inducers: the label advises avoiding strong inducers or increasing the dose to 400 mg; with moderate inducers the dose is increased to 400 mg.
  • Medicines that are P-gp substrates should be taken at least 4 hours apart from daraxonrasib; avoid cyclosporine A.
  • A pregnancy test is needed before treatment. Contraception is advised during treatment and for 1 week after the last dose; breastfeeding is not recommended during treatment and for 1 week after the last dose.
Dosing

How daraxonrasib is taken (US label)

Daraxonrasib is taken by mouth once a day. Treatment continues until disease progression or unacceptable toxicity, and the dose is reduced for side effects. Your oncologist decides the dose.[2]

StepDaily doseWhen
1300 mgRecommended starting dose, once daily
2200 mgFirst dose reduction for adverse reactions
3150 mgSecond dose reduction
–StopPermanently discontinue if 150 mg is not tolerated

Recommended dose: 300 mg once daily. Some medicines change the dose (see interactions). The doses in the table are label information, not a personal recommendation.[2]

What the main study showed

RASolute 302 (NCT06625320) was a randomised study of 500 adults with metastatic pancreatic adenocarcinoma, comparing daraxonrasib with physician's-choice chemotherapy (1:1).[1]

Median overall survival was 13.2 months (95% CI 10.0–NE) with daraxonrasib versus 6.7 months (5.8–8.0) with chemotherapy; HR 0.40, p < 0.0001. Median progression-free survival was 7.2 months (5.7–7.5) versus 3.6 months (2.9–4.2); HR 0.49, p < 0.0001. The objective response rate was 30% (25–36) versus 11% (7–15), p < 0.0001.[1]

Daraxonrasib price and quotation factors

Cost depends on the confirmed brand, 100 mg or 150 mg presentation, tablet count, quantity and destination. Request an itemized quotation. A 30-tablet bottle is not automatically a month of treatment; the prescribed daily dose determines the required quantity.

Enquiry process

How an availability enquiry works

  1. Submit an enquiry

    Tell us your country and the product information you are looking for.

  2. Eligibility review

    Medicine for World reviews destination-country restrictions and may request prescription or treatment documentation through a secure channel.

  3. Receive available options

    If the request can lawfully be supported, you may receive current product information, availability and a quotation.

  4. Complete any eligible transaction separately

    Any transaction is subject to prescription requirements, supplier checks, local law, import rules and final confirmation.

Submitting an enquiry does not guarantee availability, regulatory eligibility, import permission, delivery or a transaction.

Availability enquiry

Request an availability check

Submit a non-binding enquiry. Medicine for World will review the destination country and available options before requesting any sensitive medical documents.

This service cannot assist with medical emergencies or treatment decisions. Contact your treating healthcare professional or local emergency service.

Do not upload or include prescriptions, medical reports, passport details, payment information or other sensitive personal information in this form.

Selecting a country does not confirm that supply or import is permitted.

How can we reach you?

Provide at least one: email or WhatsApp number.

Include the country code, e.g. +44 7700 900123

Preferred contact method

Keep it general. Do not include medical details.

No payment is taken on this page. Submission does not create an order or guarantee supply.

FAQ

Frequently asked questions about daraxonrasib

What is the brand name of daraxonrasib?

RASONQUE is a brand name for daraxonrasib. Approved indications and availability can differ by country; treatment decisions must be made by a qualified oncology team.

Who makes the originator medicine?

RASONQUE was developed by Revolution Medicines, Inc. and approved by the US FDA on 26 August 2026.

How is daraxonrasib taken?

The recommended dose in the US label is 300 mg by mouth once daily until disease progression or unacceptable toxicity. For side effects the dose can be reduced to 200 mg and then 150 mg; treatment is stopped permanently if 150 mg is not tolerated.

What are the most common side effects?

In the label, rash (87%), diarrhoea (67%), stomatitis (56%), nausea (52%) and fatigue (47%) were the most frequent. Others include vomiting, abdominal pain, oedema, decreased appetite and bleeding.

Does daraxonrasib have a boxed warning?

No. The US label has no boxed warning, but it lists warnings for skin and soft-tissue reactions, mouth sores, diarrhoea, gastrointestinal perforation, lung inflammation (interstitial lung disease/pneumonitis) and harm to an unborn baby.

What did the main trial show?

In RASolute 302, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy (HR 0.40), and median progression-free survival was 7.2 versus 3.6 months (HR 0.49).

Is a generic daraxonrasib available?

This page lists 1 product represented by its supplier as containing daraxonrasib: LuciDarax by Lucius Pharma (100 mg / 150 mg tablets, as listed). Whether it is authorised in your country or equivalent to RASONQUE depends on the product and the country and must be confirmed with the national medicines authority and your treating oncologist.

Is LuciDarax equivalent to RASONQUE?

This page does not establish that. Equivalence, quality and regulatory status depend on each product and each country and must be confirmed with the national medicines authority and your treating oncologist. Clicking a brand opens its product page on the Medicine for World website.

Is daraxonrasib approved outside the United States?

This page only confirms the US approval of 26 August 2026. According to the company, the EMA's CHMP has started a phased review. Approved uses differ by country; check with your national authority.

How can I check availability?

Use the non-binding enquiry form on this page. Medicine for World reviews destination-country rules and may ask for a prescription before offering any option. An enquiry does not guarantee availability.

Transparency

Editorial and medical review

Current editorial and medical-review status is shown below. No independent medical review is claimed until it has been completed.

Written by
Daraxonrasib Editorial Team
Medically reviewed by
Independent medical review pending
Medical review date
Not yet independently reviewed
Product data last checked
October 7, 2026 (listing details as supplied; regulatory status not verified)
Independent review status
Pending; recheck immediately when official sources change and before adding any new medical claim
Sources

Sources

Medical and regulatory facts come from official product information. Product listing details come from a supplied dataset. Numbers in square brackets on this page refer to the sources below.

  1. [1]
    U.S. FDA – “FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma”Approval date (26 August 2026), indication, RASolute 302 results · Accessed: October 7, 2026
    Official source
  2. [2]
    RASONQUE (daraxonrasib) US prescribing information, Revolution MedicinesDosage form and strengths, dosing, mechanism, warnings, side effects, interactions, pregnancy · Accessed: October 7, 2026
    Official source
  3. [3]
    Revolution Medicines – “US FDA approves RASONQUE (daraxonrasib)” (press release)Originator company, brand name, EMA review status · Accessed: October 7, 2026
    Official source
  4. [4]
    Drugs.com – RASONQUE professional information (copy of the prescribing information)Cross-check of label details · Accessed: October 7, 2026
    Official source
  5. [5]
    Product listing dataset supplied by Medicine for WorldBrand name, manufacturer, strength, dosage form, pack information and product image. These listing details do not by themselves establish regulatory approval or therapeutic equivalence. · Accessed: October 7, 2026
    Supplied data – not independently verified